Premium Stanozolol(Winstrol)Powder Bodybuilding CAS:10418-03-8
Stanozolol, commonly recognized under its former brand name Winstrol, is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). In its raw, unprocessed form, it exists as a fine, crystalline powder, which is the foundational active pharmaceutical ingredient (API) before being formulated into oral tablets or injectable suspensions. This analysis provides a detailed, novel examination of premium Stanozolol powder, focusing on its unique chemical identity, applications in performance contexts, and critical pharmacological considerations, framed through a lens of scientific objectivity and risk awareness.
Chemical Identity and Distinctive Features
Unlike many anabolic steroids, Stanozolol is not esterified. Its powder form is pure 17α-alkylated stanozolol, a modification that allows oral bioavailability but imposes notable hepatotoxicity. Its defining molecular feature is the fusion of a pyrazol group to the A-ring of the steroid nucleus, a structural anomaly that sets it apart.
●Dihydrogenation: As a DHT-derivative, it cannot aromatize into estrogen. Users do not experience estrogenic side effects like gynecomastia or significant water retention.
●Moderate Androgenicity, Pronounced Anabolism: Its anabolic-to-androgenic ratio is estimated at 320:30, indicating a strong tendency to promote lean tissue synthesis with a relatively lower propensity for overtly androgenic effects, though this is highly individual.
●Hepatotoxicity Profile: The 17α-alkylation allows oral passage but is metabolized by the liver, presenting a tangible risk of hepatic stress, elevated liver enzymes, and with prolonged misuse, potential cholestasis or hepatotoxicity.
●SHBG Suppression: A key, often highlighted feature is its potent ability to lower Sex Hormone-Binding Globulin (SHBG). This increases the fraction of free, biologically active testosterone (both endogenous and exogenous), potentially amplifying the efficacy of a combined steroid regimen.
Primary Applications and Purported Benefits in Performance Contexts
In clinical medicine, Stanozolol has legitimate but narrow uses, such as treating hereditary angioedema. Its application in bodybuilding and athletics is entirely off-label and centers on specific, and often exaggerated, outcomes.
●Quality-Muscle Preservation: It is notoriously ineffective for sheer mass gain. Its primary application is during "cutting" or pre-contest phases, where the goal is to preserve lean muscle tissue under severe caloric deficit and intense cardiovascular activity. Its anti-catabolic properties are linked to its ability to antagonize glucocorticoid receptors.
●Enhanced Muscular Definition and Vascularity: Due to its lack of estrogenic activity and potential mild diuretic effect, it does not cause subcutaneous water retention. This can lead to a harder, more "dry" and vascular appearance, which is highly sought after in competitive physique sports.
●Performance Metrics: Anecdotally, users report increases in strength, speed, and power without significant weight gain, making it historically popular among athletes in weight-class or speed-dependent sports. However, these effects are inconsistent and not superior to safer, legal alternatives.
●Collagen Synthesis Paradox: Research is conflicted. Some studies suggest Stanozolol may increase collagen synthesis but decrease collagen cross-linking, potentially leading to weaker connective tissue. This, combined with disproportionate strength gains, is a hypothesized contributor to a heightened risk of tendon injury.
Pharmacokinetics: Dosage, Cycle Architecture, and Half-Life
Dosage: In powder form, dosage is measured in milligrams (mg). Typical male oral dosages range from 25-50 mg daily, often split. Injectable suspensions (from the powder) are typically dosed at 50 mg every other day. Female use, though strongly discouraged due to virilization risks, is sometimes reported at 5-10 mg daily. "Premium" implies chemical purity, not safety; these doses remain hepatotoxic.
Cycle Architecture: Stanozolol is almost never used as a standalone ("solo") agent due to its suppressive effect on endogenous testosterone production. It is used as a secondary or "finishing" agent in stacks.
●Typical Cutting Stack: A base of exogenous testosterone (e.g., Testosterone Enanthate, 300-500 mg/week) to maintain androgen homeostasis, combined with Stanozolol (25-50 mg/day) for the final 6-8 weeks of a cycle. This is sometimes augmented with other non-aromatizing agents like Masteron or a mild fat-loss agent like Clenbuterol.
●Cycle Length: Oral administration is typically limited to 6-8 weeks due to liver strain. Injectable forms, while bypassing first-pass metabolism, still present hepatotoxic risk, though some users extend use to 8-10 weeks.
●Crucial Integration: A cycle must include foundational testosterone and conclude with a Post-Treatment Cycle (PTC), more accurately termed Post-Cycle Therapy (PCT).
Half-Life: This is a critical and often misstated parameter. Stanozolol's half-life is route-dependent:
●Oral: Approximately 9 hours. This necessitates split dosing (e.g., morning and evening) to maintain stable blood plasma levels.
●Intramuscular (as a suspension): Roughly 24 hours, supporting every-other-day administration.
This discrepancy is vital for planning dosing schedules and understanding the drug's clearance rate before initiating PCT.
Post-Treatment Cycle (PCT): A Physiological Imperative
The term "Post-Treatment Cycle" more accurately reflects the goal: to restore the hypothalamic-pituitary-testicular axis (HPTA) after profound suppression. Stanozolol, like all AAS, suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to testicular atrophy and crashed endogenous testosterone upon cessation. A proper PCT is not optional.
●Timing: Initiated after the last Stanozolol dose, considering its half-life. For oral forms, PCT begins 24-48 hours later; for injectable, 36-48 hours later.
●Pharmacological Agents: PCT utilizes Selective Estrogen Receptor Modulators (SERMs) and sometimes aromatase inhibitors (AIs), though AIs are less central in this non-aromatizing cycle.
○Tamoxifen (Nolvadex): A cornerstone SERM. It blocks estrogen receptors in the pituitary, prompting increased GnRH, LH, and FSH production. A typical protocol: 40 mg/day for 2 weeks, then 20 mg/day for 2-3 weeks.
○Clomiphene (Clomid): Often used in conjunction with Tamoxifen. It stimulates the pituitary similarly. A sample protocol: 50 mg/day for 2-3 weeks, then 25 mg/day for 1-2 weeks.
●Supportive Measures: PCT includes rigorous health monitoring: comprehensive blood work (testosterone, LH, FSH, lipids, liver enzymes), liver support supplements (e.g., N-acetylcysteine, TUDCA), lipid management support (omega-3s, berberine), and natural testosterone boosters (e.g., vitamin D, zinc, ashwagandha), though their efficacy is marginal compared to SERMs.
A Novel Synthesis: The Risk-Benefit Recalibration
The narrative surrounding Stanozolol often glorifies its "hardening" effects while minimizing its profound downsides. A novel perspective requires a stark recalibration:
●The Lipid Catastrophe: Stanozolol has a uniquely severe impact on lipid metabolism, drastically lowering HDL ("good") cholesterol and elevating LDL ("bad") cholesterol. This pro-atherogenic state poses a significant, long-term cardiovascular risk that far outlasts the cycle duration.
●Connective Tissue Vulnerability: The collagen synthesis paradox, coupled with rapid strength increases, creates a biomechanical mismatch, making tendons and ligaments vulnerable to rupture.
●Androgenic Effects in Disguise: Despite its "moderate" rating, androgenic side effects like hair loss (in genetically predisposed individuals), acne, and prostate inflammation are common. Virilization in women (voice deepening, clitoromegaly, hirsutism) is often rapid and irreversible.
●Legal and Ethical Status: It is a Schedule III controlled substance in the United States and banned by all major sporting bodies. Its non-medical purchase, sale, and use carry legal and professional consequences.
Clinical Data
| Trade names | Winstrol;Stromba;Androstanazol; Androstanazole; Stanazol; WIN-14833;NSC-43193; NSC-233046; |
|
CAS |
10418-03-8 |
|
Molar mass |
328.500 |
|
Formula |
C21H32N2O |
|
Purity |
Above 98% |
|
Apprarance |
White crystalline powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785
Conclusion: A Legacy Compound in a Modern Context
Premium Stanozolol powder represents a specific, potent, and unforgiving pharmacological tool. Its value lies strictly in a very narrow window of performance enhancement-muscle preservation in a deficit-a benefit overshadowed by a formidable array of hepatotoxic, cardiovascular, musculoskeletal, and endocrine risks. In the modern era, with advanced, selective androgen receptor modulators (SARMs) and robust peptide protocols under development, the risk-to-benefit profile of traditional 17α-alkylated steroids like Stanozolol appears increasingly anachronistic. Informed choice must be grounded not in anecdotal lore but in a sober analysis of its acute and chronic pathophysiological impacts, with the understanding that "premium" refers only to chemical purity, not to any mitigation of its inherent biological dangers. Responsible practice dictates exhaustive pre-, intra-, and post-cycle health monitoring, though the only truly risk-free strategy remains complete abstinence from non-prescribed anabolic steroids.
Hot Tags: premium stanozolol(winstrol)powder bodybuilding cas:10418-03-8, China premium stanozolol(winstrol)powder bodybuilding cas:10418-03-8 manufacturers, suppliers, factory, Anastrozole Treating and Preventing Female Breast Cancer, Boldenone Cypionate, Drostanolone Enanthate steroids, Superdrol, Testosterone Propionate for Male Hypogonadism, Trenbolone Hexahydrobenzyl Cabonate
